Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-2965
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years ; volume:24 ; number:1 ; day:19 ; month:10 ; year:2012 ; pages:301-310 ; date:1.2013
Osteoporosis international ; 24, Heft 1 (19.10.2012), 301-310, 1.2013
- Creator
-
McClung, M. R.
Balske, A.
Burgio, D. E.
Wenderoth, D.
Recker, R. R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00198-012-2175-7
- URN
-
urn:nbn:de:101:1-2019101005000591335636
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McClung, M. R.
- Balske, A.
- Burgio, D. E.
- Wenderoth, D.
- Recker, R. R.
- SpringerLink (Online service)
Other Objects (12)
Postmenopausal osteoporosis
Quality of life in post-menopausal osteoporosis
Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
Concerns on modeling postmenopausal osteoporosis on young female rats
Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women
Interleukin-33 serum levels in postmenopausal women with osteoporosis
Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis
Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis
Interaction between bone and immune cells : Implications for postmenopausal osteoporosis
Determinants of imminent fracture risk in postmenopausal women with osteoporosis
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review
Postmenopausal osteoporosis
Quality of life in post-menopausal osteoporosis
Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
Concerns on modeling postmenopausal osteoporosis on young female rats
Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women
Interleukin-33 serum levels in postmenopausal women with osteoporosis
Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis
Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis
Interaction between bone and immune cells : Implications for postmenopausal osteoporosis
Determinants of imminent fracture risk in postmenopausal women with osteoporosis
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review
Postmenopausal osteoporosis
Quality of life in post-menopausal osteoporosis
Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
Concerns on modeling postmenopausal osteoporosis on young female rats
Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women
Interleukin-33 serum levels in postmenopausal women with osteoporosis
Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis
Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis
Interaction between bone and immune cells : Implications for postmenopausal osteoporosis
Determinants of imminent fracture risk in postmenopausal women with osteoporosis
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis